Introduction
Old drugs and new drugs share at least one characteristictheir use is associated with an implicit or explicit assessment of their benefit/risk ratio. The ideal therapeutic agent has a risk equal to zero and a benefit equal to one, so that the benefit/risk ratio is infinite, a convenient way to convey the idea that the ideal therapeutic agent does not exist.
However we estimate the benefit (a measure of efficacy) and the risk (a measure of toxicity), benefits and risks have to embody an estimate of the benefit of no treatment, i.e. the spontaneous cure rate, and an estimate of the risk of no treatment. From a theoretical point of view, this could be a purely epidemiological issue. The morbidity or mortality of populations exposed and not exposed to one or more therapeutic agents could be compared and the appropriate conclusions drawn. In practice, the process of drug development and approval is not -nor can it bean epidemiological exercise. Not only are the 'populations' represented by a few hundred patients, but a potentially determinant factor for drug evaluation, such as population exposure, cannot be known before the drug is marketed.
Moreover, even if we know where we stand when we discuss benefits and risks based on hard outcomes such as stroke or death, for benefits and risks based on subjective complaints like pain, the matter is more complex: it is difficult to weigh pain in ajoint versus gastric pain following treatment with an analgesic. Even more difficult would be to choosebetween better quality of life and longer survival.
The basic question, therefore, is on what implicit benefit/risk ratio assessment the marketing approval of a new drug is based, when only a few hundred patients have been treated. The second question is whether and how this assessment can be shared by the practising physicians.
The benefits
As benefits are assessed through formal studies carried out in semi-experimental conditions versus placebo and/or reference compounds, this demonstration is partly an artificial exercise that pertains to the realm of the clinical pharmacologist or to that of the clinician with an interest in clinical research. This is probably why it is customary to consider that uncertainty is associated with the assessment ofrisks, rather than benefits. 'Society does not appreciate the fact that it is not as easy to assess drug safety as drug efficacy.", But is it really so?
Ifprimum non nocere is the accepted rule in clinical practice, drug development is meaningless without the hypothesis that a drug must do some good. The pivotal concept is that of statistical significance and, as an emergency alternative, that of meta-analysis. However, although statistical significance at the usual level of <0.05 is a ritual habit, the Manichean vision of a study as positive/negative on the basis of a magic 5% is probably unsound. When the level of significance is not reached, the analysis of confidence intervals may reveal interesting trends. If these trends are consistent across different studies it is unlikely that meta-analysis or a larger study will miss the target. This point is best exemplified by the series of post-reinfarction trials with beta-blockers".
Apart from lack of statistical power, other factors may hinder the assessment of efficacy: (1)All patients on placebo recovered, and the drug was as successful as placebo. Is it only a question of patient selection? (2) Randomization may fail. Blind randomization is effective against selection bias, but it is no guarantee against heterogeneity in baseline and the consequent differential outcome.
(3) The drug seems very effective in a few patients, but overall it cannot be differentiated from placebo, or is worse than reference: if these patients can be identified as a diagnostic or demographic category, additional studies have to be conducted in this subgroup. If the drug is more selective than our nosological classifications, we may miss an orphan drug.
The efficacy in urinary tract infections of an antibacterial agent that concentrates in the urine and to which the germ is sensitive can be demonstrated easily. So can the efficacy of many marketed betablockers in European hypertensive patients. Unfortunately, in other indications, and for other drugs, the answer is not straightforward. I am not referring to drugs that some authors would define as 'useless'S, but to drugs like antidepressants or antiepileptics. Patient comparability, spontaneous variations, diagnostic inaccuracy, discrepancies between subjective and objective endpoints, all contribute to confound the issue. In other words, the assessment of efficacy is relatively easy if we satisfy ourselves with relatively simple indicators such as blood pressure, germ counts and the like, but these can be only a proxy of the overall benefit and their equivalent may not exist in certain areas of therapeutics.
The risks
If the demonstration of the benefits of new drugs can be partially left to the academics, the risks are the main, immediate concern of the licensing authorities and manufacturers on the one hand, and of the practising physicians on the other. However, as their roles are quite different, the legitimate question is: risks for whom?
On benefit/risk assessment, the points of view of the licensing authority and practising physicians seem rather opposite, albeit complementary. The former is mainly concerned with population health, the latter with individual health. An adverse drug reaction with an estimated frequency of 116000 prescriptions can amount to several hundred cases in a country like Britain; but in the same country an individual prescriber of the drug would hardly be able to 'cause' one case in 10 years of general practise".
In this case the licensing authority may decidealthough the decision process may not be explicitthat the benefit/risk ratio is not favourable, and may withdraw the drug from the market. The majority of individual doctors would have experienced the drug as safe and would feel deprived of a therapeutic tool, provided that their patients had improved on the new drug.
On the other hand, it is unlikely that any licensing authority will consider as cause for public concern the mild to moderate postural dizziness reported in 5% of patients on a new vasodilator. The same 'event' might, however, be bothersome in the asymptomatic hypertensive; he/she will complain to hislher doctor, an alternative treatment will be given, and utilization of the new drug will decrease.
In general, one may submit that the licensing authority's benefit/risk ratio is 'weighted' by the incidence of serious adverse events, 'adjusted' by the seriousness of the indication and 'standardized' by existing therapeutic alternatives; the general practitioner's benefit/risk ratio is probably 'weighted' by compliance, a not-so-indirect indicator of quality of life and efficacy.
In the long run, the pharmaceutical industry has to share both points of view: the registration department has clearly to share the licensing authority's position whilst the marketing department has to keep in mind the product's acceptability by patients. However, these different starting points are bound to overlap when the use of the drug becomes widespread. Then, practising physicians become the generators of adverse events'' and at the same time the recipients of all the available pieces of information, once these are processed at national and international level.
This, however, requires that a new drug already be on the market. When a marketing licence is about to be granted, the results available to the licensing authority come from 1000 or 2000 patients, and the practising physicians are represented by a few experts. At this microscopiclevel the 'population' and the 'individual patient' points of view can still be maintained: the licensing authority may worry about one case of agranulocytosis in a polymedicated elderly patient, whilst all the experts but one have seen no cases of serious toxicity in their patient series and consider the drug well tolerated and effective.
The point of convergence
Despite all the valuable research in population kinetics and pharmacoepidemiology, a drug will always be dispensed for one individual patient at one precise time. The uniqueness of the patient will be maintained despite the fact that the decision to prescribe a specific drug, at a specific dose, is reached by one doctor, a group of doctors or a computer. The same unique patient will donate a grant to the university who studied the new drug or will sue the company in a court of law. The plans of the pharmaceutical industry and the decisions of the licensing authorities apply to an average John Smith who does not exist. In fact, population benefits and risks have to be translated into probabilities for the individual John Smith. Distributions give way to the only existing point estimate.
The concept of 'single patient' trials has recently been introduced as a method for research" and shows that the uniqueness of the patient can be appreciated in clinical research, but this method will not be applied in routine medical practice for a substantial period of time. Any doctor wishing to prescribe the new drug will simply read its data sheet. Therefore, the data sheet represents a unique opportunity to condense the innovations of the industry and the public health concern of the licencing authorities so as to enable the prescriber to find his/her way in prescribing for the individual patient.
To be useful, a data sheet has to be 'informative'. An informative data sheet should specify which patients will benefit from the drug and -if more than one nosological category -in which order and with which degree ofcertainty. The data sheet should make clear that one is trading illness A (with its own risks) for toxicity B (with its own probability). It has to put the prescriber in a position to prescribe on reasonable grounds, leaving open, as far as risks are concerned, the possibility of the rare effect, not detectable without extensive exposure. The information should enable the prescriber to assess, at least indirectly, the benefits and risks of the new drug versus those of the drugs he has already prescribed.
These objectives might be reached by summarizing the type of studies and the results on which the prescribing information is based. A sound practitioner will not view in the same way the statistically significant but marginal advantages observed in large trials with high placebo response (or low morbidity on placebo) on the one hand, and the advantages observed in smaller, well defined groups, on the other. In the first case the probabilities of success for an individual patient may have to rank second after the probabilities of an adverse reaction, whilst in the second case benefits may take the lead. Yet, in today's average European data sheet, these two basically different cases may both be translated into 'drug A is indicated for condition B'.
As far as the 'list' of adverse reactions is concerned, a percentage is more informative than an adjective such as 'rare', and a percentage with its sample size or a confidence interval is more informative than just a percentage. The evaluation of the prescriber may change if a spontaneous (placebo) rate or a rate of reference drugs is mentioned.
An 'informative' data sheet also supports the idea that a tentative benefit/risk ratio has been and can be assessed. 'Tentative' needs emphasis, as it is indeed paradoxical that certain prescribing information resembles the tables of the law more than a sound medical text bound to be improved as the knowledge on the drug improves.
Conclusions
Population benefits and risks and their ratio as judged from pre-marketing clinical trials are considered as assessed when they can form the reasonable basis for predictions of benefits and risks once the drug is on the market. To be meaningful for the prescriber, however, this implies at least an accurate definition of the nosological groupts) to be treated (the 'indicatiorus)'), of the demographic characteristics of the exposed, and the conditions in which safety and efficacy were studied. The kinetics and pharmacology of the drug may be useful for predictions in groups not sufficiently exposed. This body of knowledge may be condensed appropriately in the data sheet in such a way that the grounds on which the first tentative conclusions on efficacy and safety are based can be identified.
However, at this, as at later stages, general benefits and risks cannot be extrapolated mechanically to the benefit/risk ratio in the individual patient. The assessment for the individual and the consequent decisions are the crystallization of the prescriber's knowledge of both the drug and the patient, and only the prescriber can test his/her predictions, ifnecessary by prudent trial and non-negligent error. This difficult exercise -a never-ending single patient trial -is Some recent books implicit in each and every act of prescribing; its difficulties should prompt great respect for those who practise it with diligence more than contempt for those who do not.
